Lupin Limited — Important, 12-02-2025: General Updates

The Board of Directors at Lupin Limited has taken several significant decisions that could influence its strategic direction. Ms. Vinita Gupta has been reappointed as CEO for five years starting May 28, 2025, while Mr. Ramesh Swaminathan will continue as Executive Director and CFO for five years from March 26, 2025.

Lupin plans to transfer its Over-the-Counter (OTC) Consumer Healthcare Business to a newly incorporated wholly-owned subsidiary named “LUPINLIFE Consumer Healthcare Limited.” The transfer, expected to be executed through a Business Transfer Agreement by April 30, 2025, is anticipated to generate a consideration between ₹ 5,500 million to ₹ 6,500 million. This strategic move aims to enhance operational performance and sharpen focus on core prescription drug strengths.

Additionally, the Board approved the formulation of a new Employee Stock Option Scheme 2025, allowing for the grant of up to 10 million options to eligible employees, emphasizing potential employee engagement and retention strategies. The actions taken reflect a proactive approach to align the company’s structure with its growth ambitions in the competitive pharmaceutical landscape, signaling a positive outlook for investors.